全文获取类型
收费全文 | 9008篇 |
免费 | 618篇 |
国内免费 | 64篇 |
专业分类
耳鼻咽喉 | 62篇 |
儿科学 | 215篇 |
妇产科学 | 192篇 |
基础医学 | 1575篇 |
口腔科学 | 121篇 |
临床医学 | 887篇 |
内科学 | 2300篇 |
皮肤病学 | 125篇 |
神经病学 | 809篇 |
特种医学 | 177篇 |
外科学 | 706篇 |
综合类 | 41篇 |
一般理论 | 1篇 |
预防医学 | 790篇 |
眼科学 | 131篇 |
药学 | 767篇 |
中国医学 | 28篇 |
肿瘤学 | 763篇 |
出版年
2024年 | 11篇 |
2023年 | 117篇 |
2022年 | 263篇 |
2021年 | 401篇 |
2020年 | 208篇 |
2019年 | 277篇 |
2018年 | 325篇 |
2017年 | 235篇 |
2016年 | 226篇 |
2015年 | 319篇 |
2014年 | 357篇 |
2013年 | 506篇 |
2012年 | 718篇 |
2011年 | 724篇 |
2010年 | 391篇 |
2009年 | 368篇 |
2008年 | 613篇 |
2007年 | 654篇 |
2006年 | 584篇 |
2005年 | 534篇 |
2004年 | 437篇 |
2003年 | 436篇 |
2002年 | 392篇 |
2001年 | 24篇 |
2000年 | 38篇 |
1999年 | 49篇 |
1998年 | 72篇 |
1997年 | 52篇 |
1996年 | 35篇 |
1995年 | 23篇 |
1994年 | 11篇 |
1993年 | 16篇 |
1992年 | 10篇 |
1991年 | 10篇 |
1989年 | 8篇 |
1988年 | 8篇 |
1987年 | 11篇 |
1986年 | 10篇 |
1985年 | 16篇 |
1984年 | 11篇 |
1982年 | 7篇 |
1981年 | 22篇 |
1980年 | 10篇 |
1978年 | 12篇 |
1977年 | 14篇 |
1976年 | 8篇 |
1975年 | 8篇 |
1974年 | 7篇 |
1971年 | 6篇 |
1966年 | 6篇 |
排序方式: 共有9690条查询结果,搜索用时 15 毫秒
81.
82.
83.
Feuerstadt Paul Aroniadis Olga C. Svedlund Felicia L. Garcia Mariana Stong Laura Boules Mena Khanna Sahil 《Digestive diseases and sciences》2022,67(7):2763-2770
Digestive Diseases and Sciences - Clinical trials have demonstrated the efficacy of FMT for reduction in CDI recurrences (rCDI), but this treatment and its reporting in the literature has... 相似文献
84.
Is visfatin an adipokine or myokine? Evidence for greater visfatin expression in skeletal muscle than visceral fat in chickens 总被引:9,自引:0,他引:9
Krzysik-Walker SM Ocón-Grove OM Maddineni SR Hendricks GL Ramachandran R 《Endocrinology》2008,149(4):1543-1550
Visfatin, an adipokine hormone produced primarily by visceral adipose tissue in mammals, has been implicated in the immune system, cellular aging, and glucose metabolism. Increased visceral adiposity and hyperglycemia have been correlated with elevated plasma visfatin levels in humans. The present study investigated visfatin cDNA and protein expression as well as plasma visfatin levels in chickens that are selected for rapid growth and are naturally hyperglycemic relative to mammals. By RT-PCR, we detected visfatin cDNA in multiple tissues in the chicken. The deduced amino acid sequence of full-length chicken visfatin was 92-93% homologous to mammalian visfatin. Using real-time quantitative PCR and Western blotting, chicken skeletal muscle was found to contain 5- and 3-fold greater quantities of visfatin mRNA and protein than abdominal fat pad, respectively. Visfatin mRNA and protein quantities were not significantly different among sc and visceral adipose tissue depots. Skeletal muscle visfatin mRNA and protein quantities as well as plasma visfatin levels determined by enzyme immunoassay were significantly higher in 8-wk-old compared with 4-wk-old chickens, possibly due to rapid skeletal muscle growth and visceral fat accretion occurring in broiler chickens during this period. However, fasting and refeeding did not affect plasma visfatin levels in the chicken. Collectively, our results provide novel evidence that skeletal muscle, not the visceral adipose tissue, is the primary source of visfatin in chickens, thereby raising the possibility that visfatin may be acting as a myokine affecting skeletal muscle growth and metabolism. 相似文献
85.
Anticardiolipin antibody (aCL), anti-beta2 glycoprotein I antibodies, and lupus anticoagulant (LA) are the only laboratory tests considered within the revised criteria for the classification of the antiphospholipid syndrome (APS). Recently, antibodies against phosphatidylserine-prothrombin complex (aPS/PT) have been detected, and these antibodies, rather than antibodies against prothrombin alone, are closely associated with APS and LA. The sensitivity and specificity of aPS/PT for the diagnosis of APS were assessed in a population of patients with a variety of autoimmune disorders. aCL and aPS/PT have similar diagnostic value for APS, therefore aPS/PT should be further explored, not only for research purposes but also as a candidate for one of the laboratory criteria for the classification of the APS. 相似文献
86.
Fofanova OV Evgrafov OV Polyakov AV Poltaraus AB Peterkova VA Dedov II 《The Journal of clinical endocrinology and metabolism》2003,88(2):820-826
Isolated GH deficiency (IGHD) is characterized by genetic heterogeneity, both in familial and sporadic cases. To determine if this statement can be applied to the Russian population, we performed screening for mutations in the GH-1 gene in children living in Russia with IGHD. Twenty-eight children from 26 families with total IGHD were studied. DNA fragments, covering each of four (2-5) exons of GH-1 were amplified using PCR. Single-strand conformation polymorphism analysis followed by direct DNA sequencing identified five heterozygous mutations of splicing in intron 2, intron 3, and exon 4 of GH-1; three of them were not previously reported. We concentrated here on dominant-negative mutations causing IGHD type II, which were as follows: 1) A>T transversion of the second base of the 3'-acceptor splice site of intron 2 (IVS2 -2A>T); 2) T>C transition of the second base of the 5'-donor splice site of intron 3 (IVS3 +2T>C); 3) G>A transition of the first base of the 5'-donor splice site of intron 3 (IVS3 +1G>A). Our data indicate allelic heterogeneity of IGHD type II (IGHD II). However, all mutations in Russian IGHD II patients affect splicing, a striking difference from the mutation spectrum of other IGHD forms. The IVS2 -2A>T mutation is the first identified mutation in intron 2 of GH-1. The 5'-donor splice site of intron 3 of GH-1 is a mutational hot spot, and the IVS3 +1G>A mutation can be considered to be a common molecular defect in IGHD II in Russian patients. 相似文献
87.
Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation 总被引:6,自引:0,他引:6
Rieger K Marinets O Fietz T Körper S Sommer D Mücke C Reufi B Blau WI Thiel E Knauf WU 《Experimental hematology》2005,33(5):605-611
OBJECTIVE: Plasticity of hematopoietic stem cells (HSC) has gained major interest in stem cell research. In order to investigate whether HSC may differentiate into mesenchymal stem cells (MSC), we assessed chimerism in peripheral blood (PB), mononuclear cell fractions (MNC) of bone marrow, and MSC derived from bone marrow (BM) from 27 up to 4225 days after allogeneic transplantation. PATIENTS AND METHODS: We applied fluorescence in situ hybridization using X/Y gene probes in sex-mismatched and STR-PCR in sex-matched patients. MSC could have been generated in 27 of 55 bone marrow samples derived from 20 patients. Fifteen patients received peripheral blood stem cell transplants (PBSCT), including CD34-selected PBSCT in two. Five patients received bone marrow. RESULTS: While all patients had chimerism in PB and MNC of the BM, in all but one patient BM-derived MSC were of recipient origin. This single patient showed reproducibly MSC of donor origin in a frequency of 1% after having received a CD34-selected PBSCT. Looking at graft collections, MSCs were easily generated from BM specimens, while no MSC could be derived from PBSC samples. CONCLUSION: Even though HSC have been found to differentiate into a variety of nonhematological cell types, they usually do not differentiate into MSC after allogeneic transplantation. 相似文献
88.
Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia 总被引:9,自引:2,他引:9
In contrast to severe aplastic anemia (sAA), the appropriate management of patients with moderate pancytopenia is unclear. In this study, we examined the efficacy of a humanized monoclonal antibody recognizing interleukin-2 receptor (daclizumab), which has proven to be a successful immunosuppressive agent in solid organ and bone marrow transplantation. We treated 17 patients with moderate aplastic anemia (mAA) with 1 mg/kg every 2 weeks for 3 months. mAA was defined as depression of 2 of the 3 blood counts: absolute neutrophil count 1200/mm3 or less, platelet count 70,000/mm3 or less, hemoglobin level 8.5 g/dL or lower, and absolute reticulocyte count 60,000/mm3 or less. The primary end point of our protocol was a hematologic response in at least one affected peripheral blood value. Daclizumab had little toxicity. Six of the 16 (38%) evaluable patients responded to treatment. Two patients with previously chronic disease showed complete return of normal counts, which were sustained for more than 2 years following treatment. Four patients had single-lineage responses. Two previously transfusion-dependent patients became transfusion independent; one patient with many neutropenia-related infections had a normal neutrophil count following treatment. Daclizumab appears safe; its efficacy in this pilot protocol suggests that expanded study of this monoclonal antibody in immune-mediated bone marrow failure syndrome is warranted. 相似文献
89.
Inés Fajardo-Martos Olga Roda Ramón Zambudio-Periago Aurora Bueno-Cavanillas Fidel Hita-Contreras Indalecio Sánchez-Montesinos 《Revista brasileira de fisioterapia (S?o Carlos (S?o Paulo, Brazil))》2018,22(3):205-214
Objective
To determine and compare specific factors that could be associated and predictive with successful prosthetic rehabilitation in major lower-limb amputations.Methods
A 15-year long (2000–2014) retrospective observational cohort study was conducted. Two different criteria were used to define successful prosthetic rehabilitation: (1) the ability to walk at least 45 m, regardless of assistive devices; and (2) walking >45 m without other ambulatory aids than one cane (if required). Age, gender, comorbidities, cause and level of amputation, stump characteristics, ulcers in the preserved limb, and time between surgery and physical therapy were examined as predictors of successful prosthetic rehabilitation.Results
A total of 169 patients (61.60 ± 15.9 years) were included. Regarding walking ability with or without walking aids, the presence of ulcers in the preserved limb was individually associated with failed prosthetic rehabilitation (p < 0.001), while being male (OR = 0.21; 95%CI = 0.06–0.80) and transtibial level of amputation (OR = 6.73; 95%CI = 1.92–23.64) were identified as independent predictors of failure and success, respectively. Regarding the criterion of successful rehabilitation, a shorter time until rehabilitation was individually associated with improved walking ability (p < 0.013), while failure could be predicted by comorbidities (OR = 0.48; 95%CI = 0.29–0.78) and age groups of 65–75 years old (OR = 0.19; 95%CI = 0.05–0.78) and over 75 years old (OR = 0.19; 95%CI = 0.04–0.91).Conclusions
Regarding walking ability with or without walking aids, male gender and transtibial level of amputation are independently associated with failure and success respectively, whereas older age and comorbidities can predict failed prosthetic rehabilitation when assistive walking devices are considered. Future prospective cohort studies are needed to confirm these findings. 相似文献90.
Carlos A. Ramos Rayne Rouce Catherine S. Robertson Amy Reyna Neeharika Narala Gayatri Vyas Birju Mehta Huimin Zhang Olga Dakhova George Carrum Rammurti T. Kamble Adrian P. Gee Zhuyong Mei Meng-Fen Wu Hao Liu Bambi Grilley Cliona M. Rooney Helen E. Heslop Gianpietro Dotti 《Molecular therapy》2018,26(12):2727-2737